History

_x000D_ Strides Pharma Science Ltd was incorporated, originally under the name 'Strides Arcolab Ltd', on June 28th, 1990. In 2002-03, the company signed an MoU with Ribbon SRL Italy to set up a joint venture to manufacture and market Cephalosporin formulations for regulated markets. The company transferred its Contract Research and Manufacturing Division (CRAM) to the wholly owned subsidiary, Strides Research & Specialty Chemicals Ltd, effective from April 1, 2002. In 2005, the company established its new technology centre named STAR-Strides Technology and Research. They also expanded their Anti TB Facility at KRS Gardens, Bengaluru._x000D_ _x000D_ In 2008, the company completed a series of divestments and acquisitions and rearranged its business into 3 specific business segments, namely Manufacturing and R&D, International Front-ended Business-Generics and Brands and Nutraceuticals Business. In April 2009, they announced a major reorganisation of their business whereby they split their operations into 3 separate entities, namely Specialty Pharmaceuticals, Pharmaceuticals & R&D._x000D_ _x000D_ In December 2012, the company with its subsidiary Agila Specialties Private Ltd collaborated with Eli Lilly to expand the delivery of its cancer medicines in emerging markets. As a part of this arrangement, Lilly in-licensed a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialities division of Strides. _x000D_ _x000D_ In FY 2018, the company exited from the India Brand Business. In 2018-19, the R&D operations of the company remained on track with 21 ANDA filings as against the 20-25 ANDA filings planned for the year. The company also received 15 product approvals in FY 2019. This included the PARA IV approvals for Cinacalcet and Milnacipran Hydrochloride._x000D_

Business Segments

_x000D_ As per accounting terms, the company has two business segments reported, i.e. pharmaceutical and bio-pharmaceutical businesses. In terms of the diseases cured, the company’s institutional business is divided into the following categories:_x000D_

_x000D_
1. AIDS - The focus of Strides is on the production and supply of newer anti-retroviral drugs that are difficult to manufacture, including pediatric dispersible formulations, new fixed-dose molecules which Strides accesses through license agreements with Gilead, Vive Healthcare, MPP, among others.
_x000D_
2. TB or Tuberculosis - Strides has its own state-of-the-art anti-TB drug facility formulating the second-line TB drug.
_x000D_
3. Malaria - Strides has begun the supply of WHO Pre-Qualified Artemether and Lumefantrine (AL) Tablets, and also AL Dispersible tablets for pediatric use. It has ERP approval for AL 80/480 and Artesunate Suppositories caps.
_x000D_
4. Hepatitis - Strides has launched “Sofosbuvir and it’s combination drugs” in Africa, South East Asia, CIS and Latam countries for Hepatitis C treatment. This represents a paradigm shift in the existing Hepatitis C cure.
_x000D_

_x000D_ Subsidiaries_x000D_ _x000D_ As of March 31, 2023, the company has 43 subsidiaries, including:_x000D_

_x000D_
1. Altima Innovations Inc. - It is a wholly owned subsidiary engaged in trading in pharmaceutical products in the USA.
_x000D_
2. Generic Partners UK Ltd. - It is a wholly owned subsidiary that supplies and distributes generic pharmaceutical products in the UK.
_x000D_
3. Pharmapar Inc. - It is a wholly owned subsidiary that trades in pharmaceutical products in Canada.
_x000D_
4. Strides Pharma Global (UK) Ltd. - It is an Investment Holding company in the UK that is 100% owned by Strides Pharma Science.
_x000D_

_x000D_

Key Personnel

_x000D_ Mr Arun Kumar, Executive Chairperson and Managing Director_x000D_ _x000D_ Mr Kumar is the Company’s Founder and also the Promoter Director. He is a first-generation entrepreneur with an impressive track record. He founded the company in 1990 and has since led it in establishing a global reputation along with a differentiated business model._x000D_

Corporate Actions

_x000D_ The company has not performed any major corporate actions in the recent past._x000D_ _x000D_ Mergers and Acquisitions_x000D_

_x000D_
• In January 2020, the Board of Directors of the company allowed the merger of its wholly-owned subsidiary, Vivimed Life Sciences Pvt Ltd (Vivimed) into the Company.
_x000D_
• In September 2019, Strides Pharma Global Pte. Limited (SPG), a step-down subsidiary in Singapore, acquired a 70% equity stake in Fairmed Healthcare AG (Fairmed), a Switzerland-based generic pharma company.
_x000D_
• In FY 2016, the company acquired the erstwhile Ranbaxy's Solus' and Solus Care' divisions which were operating in the Central Nervous System (CNS) segment in India from Sun Pharmaceuticals Limited.
_x000D_